ClinicalTrials.gg
RecruitingNCT06334198Updated Mar 28, 2024

The Effect of Naldemedine on Opioid-induced Bowel Dysfunction

A Phase 2 interventional study of Naldemedine and Placebo in Opioid-Induced Bowel Dysfunction and Constipation, sponsored by Asbjørn Mohr Drewes. Recruiting at 1 site in Denmark. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by Asbjørn Mohr Drewes · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

Opioid-induced bowel dysfunction is a frequent condition during opioid therapy for chronic pain. Indeed, up to 90% of people on opioid treated patients experience constipation. Standard laxative treatment is often ineffective in opioid-induced constipation, but peripheral acting mu-receptor antagonists (PAMORAs) have the potential to block the effects of opioids in the gastrointestinal tract while preserving the central analgesic effect. In this study, we will investigated the effects of Naldemedine in preventing the development of opioid-induced bowel dysfunction and constipation during treatment with tramadol

02

Conditions studied

  • Opioid-Induced Bowel Dysfunction
  • Constipation
03

In context

Opioid-Induced Constipation

87 studies on the registry are indexed under Opioid-Induced Constipation; 6 are open to participants now.

This study's planned enrollment of 20 is below the median of 119 across 68 interventional studies indexed under Opioid-Induced Constipation.

Browse Opioid-Induced Constipation studies →

Lead sponsor

Asbjørn Mohr Drewes is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy (assessed by a study-affiliated medical doctor)
  • Signed
  • Able to read and understand Danish.
  • Male (to avoid influence of menstrual cycles).
  • Northern European descent (to minimize genetic variance influences on drug metabolism).
  • The researcher believes that the participant understands the study details, is compliant and is expected to complete the study.
  • Opioid naïve (no history of opioid use/addiction. Opioid use more than a year ago to treat pain post-surgery is accepted. Opioid use in connection with participation in a clinical trial more than a year ago is accepted)
  • Between 20 and 40 years of age.
  • A STAI (Spielberger State-Trait Anxiety Inventory) score in the range of 20-37 i.e., classified as "no or low anxiety" at inclusion.

Exclusion criteria

Exclusion Criteria:

Known or allergy towards the used pharmaceutical compounds or pharmaceutical compounds similar to those used in the study.

  • Less than three spontaneous bowel movements per week.
  • Participation in other studies within 14 days prior to first visit.
  • Expected need of medical/surgical treatment during the study.
  • Any diagnosed disease, which investigator concludes will affect the trial (including all complications: severe , pulmonary heart disease, severe bronchial asthma, paralytic ileus, hypercapnia, serious respiratory depression with hypoxia, moderate to severe decreased liver function, gastrointestinal obstruction or perforation, acute surgical abdominal complications such as appendicitis, Mb. Crohn's, ulcerative colitis, and toxic mega colon).

History of substance abuse (alcohol, tetrahydrocannabinol, benzodiazepine, central stimulants and/or opioids, urine drug test will be performed prior to treatment start).

  • History of major mental disorders (e.g., major anxiety, major depression or treatment with psychoactive medications etc.)
  • Metal implants or pacemaker.
  • Daily use of prescription only medicine
  • Daily alcohol consumption
  • Participation motivated by "wrongful" reasons such as poor economy or psychosocial issues e.g., problems in the family, loneliness, sadness. People with such problems may be more likely to develop substance dependence*.
  • Intake of alcohol within 48 hours before start of study period or any alcohol consumption during each study period. If consumption takes place during the study the participant will be excluded.
  • Use of any analgesic medication within 48 hours before start as well as for the duration of the study. If consumption takes place during the study the participant will be excluded.
  • Nicotine use
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Active treatment

    Naldemedine + tramadol

    Drug: Naldemedine · Drug: Tramadol

  • Placebo comparator
    Placebo treatment

    Placebo + tramadol

    Drug: Placebo · Drug: Tramadol

Interventions

  • Naldemedine is administered orally once daily in the morning in a dosage of 0.2 mg.

  • DrugPlacebo

    Placebo is administered orally once daily in the morning.

  • In both arms, tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200mg).

06

What researchers measure

Primary outcomes

  1. Total gastrointestinal transit time

    Difference in hours from ingestion of a 3D Transit Capsule to expulsion of the capsule during active and placebo treatment

    Time frame: From day 4 to day 8

  2. Colorectal transit time

    Difference in hours from the entering in the colon of a 3D Transit Capsule to expulsion of the capsule during active and placebo treatment

    Time frame: From day 4 to day 8

Secondary outcomes

  1. Constipation symptoms

    Measured on the Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire (ranging from 0 (symptom absent) to 4 (very severe).

    Time frame: From day 1 to day 10

  2. Bowel movement frequency

    Number of spontaneous bowel movements per day

    Time frame: From day 1 to day 10

  3. Stool consistency

    Rated on the Bristol Stool Form Scale (ranging from type 1 (constipation) - type 7 (diarrhea))

    Time frame: From day 1 to day 10

  4. Gastrointestinal symptoms

    Measured on the Gastrointestinal Symptom Rating Score (GSRS) questionnaire (ranging from 0 (no discomfort) to 6 (very severe discomfort)

    Time frame: Day 1 and day 10

  5. Opioid-induced constipation

    Measured by the Bowel Function Index (BFI) questionnaire (ranging from 0 (not at all) to 100 (very strong).

    Time frame: Day 1 and day 10

  6. Diagnostic evaluation of opioid-induced constipation

    Assessed using the Rome IV C6 criteria

    Time frame: Day 10

  7. Colonic motility patterns

    Number of motility patterns in the colon measured by the 3D Transit Capsule

    Time frame: From day 4 to day 8

  8. Opiate withdrawal symptoms

    Measured by the Subjective Opiate Withdrawal Scale (ranging from 0 (not at all) to 4 /extremely)

    Time frame: Day 13, 14 or 15

  9. Colon volume

    Volumetric quantification of the colon measured using T2-weighted MRI images

    Time frame: Day 10

  10. Colonic water content

    Analysis of colonic water content measured using heavily T2-weighted MRI images

    Time frame: Day 10

  11. Defecation assessment

    Analysis of rear-front pressure during a simulated defecation using the Fecobionics device

    Time frame: Day 1 and day 10

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Mar 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2024
First posted
Mar 27, 2024
StartActual
Mar 12, 2024
Primary completionEst.
Mar 2025
CompletionEst.
Mar 2025
Last update
Mar 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06334198
Lead sponsor
Asbjørn Mohr Drewes
Responsible party
Asbjørn Mohr Drewes (Professor, Aalborg University Hospital) — Sponsor-investigator
First posted
Mar 27, 2024
Start date
Mar 12, 2024
Primary completion
Mar 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
Mar 28, 2024

Study contacts

Asbjørn Mohr Drewes
Contact
amd@rn.dk
+45 97 66 35 62
Asbjørn Mohr Drewes
principal investigator · Aalborg University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naldemedine

Start the discussion